Company Overview of IDT Biologika GmbH
IDT Biologika GmbH develops, manufactures, and markets animal health products, human vaccines, and pharmaceuticals. Its animal health products include vaccines and pharmaceuticals for farm and companion animals; natural hormone preparations for pig production; cell-cultivated vaccines against influenza; vaccines against salmonella typhimurium and s. choleraesuis; vaccines for pigs; live salmonella vaccine against s. typhimurium and s. enteriditis for use in chickens; and vaccines for combating zoonoses. The company also provides development services for vaccines ranging from clinical phase I to III; and commercial supplies for viral and bacterial human vaccines. Its pharmaceuticals comprise ...
Founded in 1921
Key Executives for IDT Biologika GmbH
Chief Executive Officer and Managing Director
Managing Director and Head of Global Animal Health Division
Compensation as of Fiscal Year 2017.
IDT Biologika GmbH Key Developments
IDT Biologika Acquires Facility in Canada to Expand Investment in the Americas
Aug 21 17
IDT Biologika purchased a new facility in Canada that will significantly enhance the company's vaccine development and manufacturing capabilities. The companies plan to build out the facility as a technological beacon for veterinary medicine and livestock health in the region. The new IDT Biologika building in Cambridge will be home to a animal vaccine manufacturing hub serving North America. The nearly 32,000-square foot facility will support a significant increase in IDT's production capacity and innovative and efficient processes for the commercial production of animal health vaccines, including antigen production, blending-filling-packaging, storage, a clean room lab, offices and meeting areas, and bacterial research that meet high quality requirements. Automation as well as cutting-edge equipment and computing capabilities are considered in construction and installation plans.
IDT Biologika Establishes Animal Health Americas Business Unit; Appoints José Ochoa as Head of IDT Biologika Animal Health Americas
Jan 11 17
IDT Biologika announced that it has established a new organization to serve the animal health needs of veterinarians, farmers and government agencies in the Americas. IDT Animal Health Americas will leverage the company’s global expertise and technology to offer an innovative range of high-quality autogenous, wildlife and commercial vaccines and diagnostic solutions for use in animals.
José Ochoa has been appointed head of the newly formed business unit, IDT Biologika Animal Health Americas. José Ochoa, who joined IDT from Emergent BioSolutions in 2015, has been appointed head of the new regional business unit for the Americas, responsible for overall growth and operations. He takes on this new role within Animal Health while maintaining his position as Chief Business Officer with IDT Biologika Corporation in Rockville, Maryland. Jackie Gallant, Founder and President of Gallant Custom Laboratories, sits on IDT’s Scientific Advisory Board and will continue to oversee research and development of innovative autogenous biologics, with a focus on serving animal health customers throughout Canada. She will be supported by Dr. Guy Moser, General Manager, Gallant Custom Laboratories, and Sam Mostafa, Gallant Custom Laboratories, who will serve as key account manager for animal health vaccines in Canada.
IDT Biologika Wins Contract for Live Virus Filling and Finishing Services from BARDA
Oct 24 16
IDT Biologika announced that the Biomedical Advanced Research and Development Authority (BARDA) within the office of the Assistant for Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS) has awarded the company an Indefinite Quantity, Indefinite Delivery (IDIQ) contract1 to provide live virus filling and finishing services with an initial commitment of $100,000, subject to task order(s) for a maximum amount of $50 million. BARDA seeks to establish fill/finish capabilities for use of live-vectored virus products in clinical development through licensure. BARDA has contracted with IDT Biologika to provide services to support cGMP and non-GMP filling and finishing of a variety of medical countermeasure products. The company will initially provide services to support live virus/vectored vaccine fill finish and potentially for small molecule injectables, large molecule sterile injectables, monoclonal antibodies and other development-stage and FDA-approved medical countermeasures. The BARDA contract may be performed over a five-year period and addresses two types of requirements: the first being fill finish services to support the development of live/vectored virus product candidates and medical countermeasures. The second provides for rapid response readiness for fill finish services for medical countermeasures within an accelerated time frame.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|